Pegvisomant

Pegvisomant
Clinical data
Trade names	Somavert
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Pegvisomant;
Pregnancy; category	AU: B3; ;
Routes of; administration	Subcutaneous
ATC code	H01AX01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	218620-50-9 ;
IUPHAR/BPS	7485;
DrugBank	DB00082 ;
ChemSpider	none;
UNII	N824AOU5XV;
KEGG	D05394 ;
ChEMBL	ChEMBL1201515 ;
Chemical and physical data
Formula	C990H1532N262O300S7
Molar mass	22129.10 g·mol−1
	(what is this?) (verify)

Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly.^[1]^[2]^[3] It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy.^[4] It is delivered as a powder that is mixed with water and injected under the skin.^[5]

^ ^a ^b "Somavert- pegvisomant kit". DailyMed. 18 November 2021. Retrieved 18 May 2022.
^ ^a ^b "Somavert EPAR". European Medicines Agency. 17 September 2018. Retrieved 18 May 2022.
^ Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (January 2007). "Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study". European Journal of Endocrinology. 156 (1): 75–82. doi:10.1530/eje.1.02312. PMID 17218728. S2CID 12121175.
^ Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (March 2015). "Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY". Endocrine Practice. 21 (3): 264–74. doi:10.4158/EP14330.OR. PMC 4618502. PMID 25370326.
^ Scientific Discussion of Somavert (PDF) (Report). European Medicines Agency. 2004. Archived from the original (PDF) on 18 June 2018. Retrieved 17 February 2011.

[Somavert_FDA_label-1] "Somavert- pegvisomant kit". DailyMed. 18 November 2021. Retrieved 18 May 2022.

[Somavert_EPAR-2] "Somavert EPAR". European Medicines Agency. 17 September 2018. Retrieved 18 May 2022.

[Schreiber-3] Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (January 2007). "Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study". European Journal of Endocrinology. 156 (1): 75–82. doi:10.1530/eje.1.02312. PMID 17218728. S2CID 12121175.

[ReferenceA-4] Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (March 2015). "Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY". Endocrine Practice. 21 (3): 264–74. doi:10.4158/EP14330.OR. PMC 4618502. PMID 25370326.

[ema-5] Scientific Discussion of Somavert (PDF) (Report). European Medicines Agency. 2004. Archived from the original (PDF) on 18 June 2018. Retrieved 17 February 2011.

[1]

[2]

[3]

[4]

[5]